(IN BRIEF) A team at the Technical University of Munich has developed synthetic macrocyclic peptides that inhibit harmful protein aggregation linked to Parkinson’s disease. The peptides also block the interactions between proteins involved in Alzheimer’s and type 2 diabetes, which … Read the full press release
Posted in Business, Education, Financial, Germany, Healthcare, Industrial, Investment, Management, News, Science, Technology
Tagged Alzheimer’s disease, amyloid plaques, Aphrodite Kapurniotu, biomedicine research, cross-seeding inhibition, DFG, EPFL, German Research Foundation, Helmholtz Center Munich, LMU University Hospital, macrocyclic peptides, metabolic disorders, multifunctional drugs, neurodegenerative diseases, Parkinson's disease, peptide biochemistry, protein aggregation, SFB 1035, synthetic peptides, Technical University of Munich, TUM, type 2 diabetes
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?